Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | GLS | O94925 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4190379 | 0.95 | TDP1 (0.54) | TDP1L3MBTL1MAPTRAB9ASMN1; SMN2 | |
| SCHEMBL11502328 | 0.93 | TDP1 (0.57) | TDP1L3MBTL1CYP1A2CYP2C19MEN1 | |
| SCHEMBL29384939 | 0.93 | TDP1 (0.57) | TDP1L3MBTL1CYP1A2CYP2C19MEN1 | |
| SCHEMBL29991217 | 0.93 | TDP1 (0.57) | TDP1L3MBTL1CYP1A2CYP2C19MEN1 | |
| SCHEMBL4167098 | 0.93 | TDP1 (0.57) | TDP1L3MBTL1CYP1A2CYP2C19MEN1 | |
| SCHEMBL25123877 | 0.93 | TDP1 (0.57) | TDP1L3MBTL1CYP1A2CYP2C19MEN1 | |
| SCHEMBL4183460 | 0.93 | TDP1 (0.57) | TDP1L3MBTL1CYP1A2CYP2C19MEN1 | |
| SCHEMBL19585886 | 0.93 | TDP1 (0.57) | TDP1L3MBTL1CYP1A2CYP2C19MEN1 | |
| SCHEMBL4178008 | 0.93 | TDP1 (0.57) | TDP1L3MBTL1CYP1A2CYP2C19MEN1 | |
| SCHEMBL29831635 | 0.89 | GLS (0.53) | TDP1L3MBTL1MAPTRAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200123142-A1 | Substituted Cyclohexylamine Compounds | Epizyme, Inc. (US) | 2020-04-23 | — | — | US | disclosed |
| US-10577363-B2 | Substituted piperidine compounds | Epizyme, Inc. (US) | 2020-03-03 | — | — | US | disclosed |
| US-10106510-B2 | Substituted isoxazoles for treating cancer | Epizyme, Inc. (US) | 2018-10-23 | — | — | US | disclosed |
| US-20170362217-A1 | Substituted Piperidine Compounds | Epizyme, Inc. (US) | 2017-12-21 | — | — | US | disclosed |
| US-20170362191-A1 | Substituted Cyclohexylamine Compounds | Epizyme, Inc. (US) | 2017-12-21 | — | — | US | disclosed |
| EP-3193605-A1 | SUBSTITUTED PIPERIDINE COMPOUNDS | Epizyme, Inc. (US) | 2017-07-26 | — | — | EP | disclosed |
| EP-3190891-A1 | SUBSTITUTED CYCLOHEXYLAMINE COMPOUNDS | Epizyme, Inc. (US) | 2017-07-19 | — | — | EP | disclosed |
| WO-2016040502-A1 | SUBSTITUTED CYCLOHEXYLAMINE COMPOUNDS | Epizyme, Inc. (US) | 2016-03-17 | — | — | WO | disclosed |
| WO-2016040515-A1 | SUBSTITUTED PIPERIDINE COMPOUNDS | Epizyme, Inc. (US) | 2016-03-17 | — | — | WO | disclosed |
| EP-2238119-B1 | Quinazolines and related heterocyclic compounds, and their therapeutic use | VERENIGING VOOR CHRISTELIJK HOGER ONDERWIJS WETENSCHAPPELIJK ONDERZOEK EN PATIËNTENZORG (NL) | 2015-11-25 | — | — | EP | disclosed |
| WO-2000032570-A1 | HYDRAZINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2000-06-08 | — | — | WO | disclosed |
| US-4613695-A | ANTITUMOR | AKTIEBOLAGET LEO (SE) | 1986-09-23 | — | — | US | disclosed |
| EP-0106123-B1 | NOVEL N-NITROSO COMPOUNDS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND PROCESSES FOR THEIR PREPARATION | AB LEO (SE) | 1986-01-02 | — | — | EP | disclosed |
| EP-0106123-A1 | Novel N-nitroso compounds, compositions containing such compounds and processes for their preparation | AB LEO (SE) | 1984-04-25 | — | — | EP | disclosed |
| US-4159373-A | 7-Acyl-3-(sulfonic acid and sulfamoyl substituted tetrazolyl thiomethyl) cephalosporins | SMITHKLINE CORPORATION (US) | 1979-06-26 | — | — | US | disclosed |
| US-4140694-A | BACTERICIDES | SMITHKLINE CORPORATION (US) | 1979-02-20 | — | — | US | disclosed |
| US-4139701-A | BACTERICIDES | SMITHKLINE CORPORATION (US) | 1979-02-13 | — | — | US | disclosed |
| US-4118490-A | ANTIBACTERIAL ACTIVITY | SMITHKLINE CORPORATION (US) | 1978-10-03 | — | — | US | disclosed |
| US-4093723-A | ANTIBIOTICS | SMITHKLINE CORPORATION (US) | 1978-06-06 | — | — | US | disclosed |
| US-4048311-A | ANTIBACTERIAL | SMITHKLINE CORPORATION (US) | 1977-09-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10577363-B2 | Substituted piperidine compounds | SMYD3, SMYD2, SNRPD3 | TDP1 1894/4885L3MBTL1 358/4885MAPT 3826/4885 |
| US-20200123142-A1 | Substituted Cyclohexylamine Compounds | SMYD3, SMYD2, SNRPD3 | TDP1 1341/4885L3MBTL1 129/4885MAPT 3582/4885 |
| US-20170362217-A1 | Substituted Piperidine Compounds | SMYD3, SMYD2, SNRPD3 | TDP1 1894/4885L3MBTL1 358/4885MAPT 3826/4885 |
| US-20170362191-A1 | Substituted Cyclohexylamine Compounds | SMYD3, SMYD2, SNRPD3 | TDP1 1341/4885L3MBTL1 129/4885MAPT 3582/4885 |
| US-10106510-B2 | Substituted isoxazoles for treating cancer | SMYD3, SMYD2, SNRPD3 | TDP1 1354/4885L3MBTL1 509/4885MAPT 4295/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.